Delivery Order SPE2DB25D3021-SPE2DB26FQWVG
- Not listed
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $1,385.42 on August 19, 2025, for the supply of Insulin Aspart 100 Unit/mL vials (10mL). This firm fixed-price delivery order, with an ultimate completion date of August 20, 2025, represents a child contract under AmerisourceBergen's larger indefinite delivery contract (IDC) with DLA Troop Support Medical. The award was made through competitive procurement with no set-aside designation. The place of...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,194.80 to AmerisourceBergen Drug Corp for the supply of Insulin Aspart 100 Unit/mL vials (10mL) under a firm fixed-price contract. The award, issued on September 19, 2025, with an ultimate completion date of September 22, 2025, represents a competitively awarded non-set-aside procurement. Performance of this delivery order will be fulfilled from the vendor's location in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency awarded a $4,196.47 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Insulin Aspart 100 Unit/mL vials (10mL) on July 31, 2025, with an ultimate completion date of August 1, 2025. This non-set-aside, competitively awarded contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $4,205.06 to AmerisourceBergen Drug Corp for the supply of Insulin Aspart 100 Unit/mL vials (10mL) on August 28, 2025, with completion scheduled for August 29, 2025. This competitively awarded, firm fixed-price delivery order represents a non-set-aside procurement and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The contract is classified as a child award under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 2, 2025, for the supply of Insulin Aspart 100 Unit/mL vials (10mL) with a ceiling value of $1,197.73. This is a firm fixed price delivery order with no set-aside designation, meaning the contract was competitively awarded. The performance location is AmerisourceBergen's Corporate Office in Conshohocken, Pennsylvania, with an ultimate completion date of June 3, 2025. This delivery order represents a child...
- The Defense Logistics Agency (DLA) awarded a $1,883.76 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Insulin Aspart 100 Unit/ML vials (10 mL) with an ultimate completion date of September 30, 2025. This non-set-aside award was issued on September 29, 2025, and will be fulfilled from the vendor's location in Conshohocken, Pennsylvania. The delivery order represents a child contract action under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 6, 2025, for the supply of Insulin Aspart 100 Unit/mL vials (10mL) at a ceiling value of $3,835.96. This contract is structured as a firm fixed price delivery order with no set-aside designation, indicating it was competitively awarded. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order represents a single...
- The Defense Logistics Agency awarded a $5,030.35 firm fixed-price delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Insulin Aspart 100 Unit/mL vials (10 mL). The contract is non-set-aside and competitively awarded, with performance scheduled for completion by August 13, 2025, at the awardee's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical,...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $6,585.72 for the supply of Insulin Aspart 100 Unit/mL vials (10mL) under a firm fixed price contract. This non-set-aside award was issued on August 11, 2025, with an ultimate completion date of August 12, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a routine pharmaceutical procurement supporting federal medical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Insulin Aspart 100 Unit/mL vials (10mL) valued at $2,843.25 on July 24, 2025, with an ultimate completion date of July 25, 2025. This non-set-aside, firm fixed price delivery order will be performed at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. The contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- SPE2DB25D3021Indefinite Delivery Contract
- SPE2DB25D3021-SPE2DB26FQWVGDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,989.67 to AmerisourceBergen Drug Corp for the supply of Insulin Aspart 100 Unit/mL vials (10mL) on October 20, 2025, with completion targeted for October 21, 2025. The contract is structured as a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. Performance will be executed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999,999,999.00 and extending through December 2026. AmerisourceBergen Drug Corp serves as a critical pharmaceutical distributor for federal medical procurement, particularly supporting military and veteran healthcare systems through the Defense Health Agency and related government healthcare entities. The company's extensive federal contract portfolio demonstrates its capability to supply a broad range of pharmaceutical products, including diabetes medications, neurological treatments, pain management pharmaceuticals, antibiotics, and specialized medical supplies across multiple therapeutic domains. This specific delivery order represents a routine pharmaceutical supply transaction within the company's ongoing role as a prime vendor supporting federal medical supply chain operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.0k | 10/20/25 |